

ARTICLE OPEN



Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia

Alessandro Mauriello ¹✉, Manuel Scimeca ¹, Ivano Amelio ^{1,2}, Renato Massoud ¹, Antonio Novelli ³, Francesca Di Lorenzo ⁴, Susanna Finocchiaro ¹, Carolina Cimino ¹, Rossana Telesca ¹, Marcello Chiocchi ¹, Qiang Sun ⁵, Ying Wang ⁶, Yufang Shi ^{6,7,8,9}, Giuseppe Novelli ^{4,10,11}✉ and Gerry Melino ^{1,12}✉

© The Author(s) 2021

While vaccination is the single most effective intervention to drastically reduce severe disease and death following SARS-CoV-2 infection, as shown in UK and Israel, some serious concerns have been raised for an unusual adverse drug reaction (ADR), including vaccine-induced immune thrombotic thrombocytopenia (VITT) with concurrent low platelets as well as capillary leak syndrome. In fact, the overall safety of the vaccine is highlighted by the low frequency of ADR considering that in UK, by the early June, 40 million first doses and 29 million second doses have been injected; nonetheless, 390 thrombotic events, including 71 fatal events have been reported. Interestingly, the cases reported low platelet counts with the presence of anti-platelet factor-4 (PF4) antibodies, indicating an abnormal clotting reaction. Here, out of three referred cases, we report a post-vaccine clinical case of fatal thrombosis with postmortem examination and whole exome sequencing (WES) analysis, whose pathogenesis appeared associated to a preexisting condition of thrombocytopenia due to myelodysplasia.

Cell Death and Disease (2021)12:762; <https://doi.org/10.1038/s41419-021-04058-z>

INTRODUCTION

Therapeutic approaches to cure COVID-19 are still under development, despite the recent significant progress in the design of monoclonal antibodies [1, 2], inhibitors of proteases [3–5], and the identification of novel targets, such as the HETC E Ligase, Itch [6, 7]. The vaccination against the infection of SARS-CoV-2 has been proven so far as the most effective intervention to limit damage to human health and to prevent expansion of the economical and societal implications associated to the pandemic [8–10]. While governments and health institutions have deployed major resources to promptly reach herd immunity by vaccination, reports of rare thrombosis events have threatened the regular course of the programmes. Following immunization with adenovirus-vector COVID-19 vaccines ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2-S (Johnson&Johnson/Janssen), cerebral venous thromboses have been observed with specific cases resulted in fatal outcome [11–13]. Little scientific literature is currently available and most of the investigated cases appeared associated to a clinical picture of moderate-to-severe thrombocytopenia and thrombotic complications beginning 10–15 days after vaccination, resembling severe heparin-induced thrombocytopenia (HIT) [14].

HIT is well-characterized as a prothrombotic condition triggered by antibodies against platelets, that recognize the molecular complex generated by interaction of cationic platelet factor-4 (PF4) and anionic heparin [14]. Frequently, patients with post COVID-19 vaccination thrombosis displayed high level of anti-PF4 antibodies in absence of heparin administration, thus leading to the definition of vaccine-induced immune thrombotic thrombocytopenia [13].


Here out of three referred cases, we report a case of fatal thromboembolism following administration of the first dose of ChAdOx1 nCoV-19 (AstraZeneca). We conducted an in-depth postmortem analysis, which revealed a bone marrow focal megakaryocyte hyperplasia associated with morphological dysplastic changes. The patient also displayed peripheral thrombocytopenia, with undetectable level of serum anti-PF4 antibodies. WES revealed no significant genetic alterations in genes associated to thrombocytopathies, complementopathies, and platelets dysfunction diseases. Thus, the underlying myelodysplasia appeared causative of a vaccine-independent preexisting thrombocytopenia that predisposes to severe adverse drug reaction to the COVID-19 immunization.

¹Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133 Rome, Italy. ²School of Life Sciences, University of Nottingham, Nottingham, UK. ³Laboratory of Medical Genetics, Translational Cyto-genomics Research Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy. ⁴Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. ⁵Laboratory of Cell Engineering, Institute of Biotechnology; Research Unit of Cell Death Mechanism, Chinese Academy of Medical Science, 2020RU009, 20 Dongda Street, Beijing 100071, China. ⁶Institute of Nutrition and Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. ⁷The Third Affiliated Hospital of Soochow University, Changzhou, China. ⁸The Child Health Institute of New Jersey, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA. ⁹Institutes for Translational Medicine, Soochow University, Suzhou, China. ¹⁰IRCCS Neuromed, Pozzilli, IS, Italy. ¹¹Department of Pharmacology, School of Medicine, University of Nevada, Reno, NV 89557, USA. ¹²DZNE German Center for Neurodegenerative Diseases, Bonn, Germany. ✉email: alessandro.mauriello@uniroma2.it; novelli@med.uniroma2.it; melino@uniroma2.it

Edited by B. Zhivotovskiy

Received: 23 June 2021 Revised: 26 July 2021 Accepted: 26 July 2021

Published online: 03 August 2021



Lab Analysis	Result	Ref Value
Ab Anti-SARSCoV2	109 BAU/ml	pos > 0.8
D-dimer	10 mg/mL	pos > 0.0005
Platlets	32,000/uL	150K-450K
HIT IgG anti-PF4	0,38 U/mL	pos > 1
IgG anti-Cardiolipin	50,2 U/mL	pos > 20

Fig. 1 Thrombosis and preexisting myelodysplasia. Computed tomography angiography (CTA); **A** coronal view shows right internal jugular vein thrombosis (arrow), **B** axial view shows right transverse sinus thrombosis (arrow). A massive hemorrhagic focus is observed on right hemisphere (*). **C** Hematoxylin and eosin stain shows numerous degranulated megakaryocytes (arrows) (scale bar 100 μ m). **D** Normal megakaryocyte characterized by large and abundant cytoplasm with more than 50 mature platelet granules (scale bar 5 μ m). **E** Electron micrograph displays a megakaryocyte with few mature platelet granules (square) and numerous mitochondria (scale bar 3 μ m). **F** A completely degranulated megakaryocyte (scale bar 5 μ m). Table reports laboratory test results (full results in Supplementary Table 2).




Fig. 2 Light and transmission electron microscopy of bone marrow. **A** Haematoxylin and eosin stain shows two large size degranulated megakaryocytes (asterisks) (scale bar 20 μ m). **B** Toluidine blue stain displays a degranulated megakaryocytes with a large and segmented nucleus (asterisks) (scale bar 20 μ m). **C, D** Degranulated megakaryocytes with fragmented nuclei (asterisks) (scale bar 10 μ m). **E** Electron micrograph shows a megakaryocyte with rare immature/degenerated platelet granules. The cytoplasm included large amount of degenerating electron-dense material (asterisk). The square highlights high magnification of an immature platelet granule (scale bar 5 μ m). **F** A megakaryocyte with no/rare platelet granules (scale bar 5 μ m).

RESULTS AND DISCUSSION

Starting from day +1 after receiving the vaccine ChAdOx1 nCoV-19 (Oxford-Astrazeneca), a 48-year-old Caucasian woman reported progressive headache, back pain, moderate right lower limb pain, and disseminated ecchymosis that required hospitalization on day +18 for 7 days (S. Eugenio Hospital, Rome).

The clinical history included allergy to penicillin and an episode of thrombocytopenia in 2016. At the physical examinations, the patient appeared afebrile, with good hemodynamic compensation, absence of abnormal sounds at respiratory auscultation, soft abdomen and normal neurological objectivity, with a blood pressure of 214/125 mmHg. Laboratory tests showed a D-dimer value >10000 ng/mL and thrombocytopenia lower than 32000 platelets/ μ L. A pulmonary angio-CT showed thrombo-embolic filling defects affecting the pulmonary artery, in absence of any densitometric changes in the parenchyma. Venous echo-color doppler of the lower limbs showed absence of previous and/or concurrent deep venous obstructions. Low molecular weight heparin was administered.

On day +22, the patient required a transfer to the neurology intensive care unit to improve her management, as a significant intensification of headache, confusion, nausea, and vomiting emerged. The new therapeutic strategy included anti-hypertensive, and oral double (dabigatran 110 mg/die + rivaroxaban 30 mg/die) anti-coagulants in addition to i.v. methylprednisolone. In the following two days a drastic worsening of patient's neurological symptoms including altered consciousness, strength deficit in the left side and right gaze deviation. An emergency skull CT documented massive right temporo-occipital intraparenchymal hemorrhage, extending to the ventricular system associated to midline shift; CT angiography investigating intra- and extra-cranial circulation showed thrombotic phenomena of the sigmoid transverse sinus and of the right internal jugular vein (Fig. 1A). The administration of Dabigatran antagonists and a decompressive craniectomy (day +23) was urgently performed. The patient remained comatose in intensive care for about 2 weeks, till day +16 after surgery (or day +39), when brain death was diagnosed.




Fig. 3 Histological analysis of lung thrombi. A–D Histological and electron microscopy analysis of lung tissues. Both PAS (A) and silver (B) staining show vascular thrombi (asterisks) in lung capillaries (scale bar 100 μ m). C Electron micrograph shows vascular thrombi characterized by microvascular fibrin deposition (asterisks). The thrombi include degenerated monocytes (arrows) (scale bar 5 μ m). D Image displays vascular thrombi with microvascular fibrin deposition (asterisks) and well-preserved pericytes (arrows) (scale bar 5 μ m).

Autoptic examination revealed a massive cerebral hemorrhage complicated by a purulent abscess involving the right fronto-temporo-parietal lobes, the nucleus of the right base, with midline shift and wedging of the cerebellar tonsils and an internal and external haemocephalus (Fig. 1B and Supplementary Fig. 1). Bilateral confluent foci of bronchopneumonia associated to a right apical pulmonary infarction of both lungs were also observed (Supplementary Fig. 2A, B). Postmortem analysis of bone marrow, including hematoxylin and eosin stain, immunohistochemistry, and transmission electron microscopy (TEM), showed focal megakaryocyte hyperplasia associated with morphological dysplastic changes. Abnormalities included non-lobulated or hypoblobulated megakaryocytes, increase of cytoplasm, and separate or dark pycnotic nuclei (Fig. 1C–F and Fig. 2). Normal megakaryocytes (30–70 μ m of diameter), characterized by large and hyperploid nuclei, accounted only 20% of the total population (Fig. 1B) and displayed more than 50 platelet granules ($65,56 \pm 8,67$) (Fig. 1D). Conversely, the largest majority of megakaryocytes (~70%) displayed a significant impairment in the platelet granule formation (Fig. 1E, F), with degranulated cytoplasm and rare immature platelet granules ($11,45 \pm 4,14$) (Fig. 1E). Five to ten percent of megakaryocytes were characterized by a complete impairment of platelet granules formation (Fig. 1F). TEM analysis of lung tissues further confirmed the frequent occurrence of vascular septic thrombi characterized by microvascular fibrin deposition (Fig. 3). Degenerated inflammatory cells, such as

monocytes, were observed in several organized thrombi; vessels displayed no pericytes alteration. Signs of long standing petechiae were noted on the skin; hematoxylin–eosin staining reported a sclerosis of the dermis associated to nonspecific vasculitis infiltrated by CD3-positive T lymphocytes (Supplementary Fig. 3). All together, the ultrastructural data suggest the occurrence of a thrombocytopenia related to the impairment of megakaryocytes differentiation. Nevertheless, a paradoxical effect was observed in the lung with diffuse pulmonary thrombosis.

We also performed a WES genetic analysis on the patient's PBMC. We studied more in details 64 genes involved in thrombocytopathies, complementopathies, and several platelets dysfunction diseases [15, 16] and detected a total of 585 genetic variants. Introducing a cutoff at MAF 0.01, we selected 11 rare putative variants (1,88%): 1 out of these is a missense variant, 10 out of the total are intronic variants (Supplementary Table 1). According to the American College of Medical Genetics guidelines, these variants can be classified as benign and/or of unknown significance; also, the *SERPINF2* missense variant emerged as benign and tolerated in all in silico prediction tools.

While the patient displayed several autoimmune autoantibodies (Supplementary Table 2), we failed to detect anti-PF4 antibodies, in contrast with most of the reported cases [11–14, 17], but in keeping with a similar case of ChAdOx1 nCoV-19 vaccine (Astrazeneca/Oxford) administration [18]. This suggests that in addition the immune thrombotic thrombocytopenia associated

with antibodies that recognize PF4 and activate platelets through their Fcγ receptors, leading to autoimmune HIT [19, 20], other causes of thrombocytopenia, such as megakaryocyte dysplasia, could lead to potential life-threatening ADR. The underlying molecular events are not clear, even though platelets express ACE2, which can be triggered by SARS-CoV-2 binding to enhance thrombosis [21]; hence suggesting a stoichiometric relationship leading to the thrombotic event. Conversely, the vaccine administration has been associated to events of anti-PF4/polyanion antibodies production [22], but not in our specific case. We also detected the presence of NETosis, in keeping with its driving role in HIT [23], but only at a late stage and in the brain tissue, whilst the lung was depleted of neutrophils. Therefore, in keeping with the highly complex pattern of immune response to SARS-CoV-2, a sensible recommendation seems to be to avoid vaccination in thrombocytopenic patients and/or myelodysplastic patients or at least keep them under very strict control (<https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>).

MATERIAL AND METHODS

Histology

Several samples of heart (left and right ventricles, septum, coronary tree), lungs (at least one for each lobe), liver, spleen, kidneys, bone marrow, brain, cerebellum, transverse sinus of dura mater, and skin (long standing petechiae) were fixed in buffered formalin and paraffin embedded. Serial sections for each sample were stained with hematoxylin and eosin (H&E). Also, PAS, Reticulum and Grocott silver stains were performed.

Immunohistochemistry

Immunohistochemical analyses were performed on 3-μm-thick paraffin sections. Briefly, EDTA citrate pH 7.8 buffer was used for the antigen retrieval. Sections were then incubated with the following pre-diluted primary antibodies: CD3 (clone Cd 2GV6, Rabbit Monoclonal, Ventana, Roche), CD20 (clone L26, mouse monoclonal), CD68 (clone KP-1, mouse monoclonal), CD117 (clone EP10, rabbit monoclonal), CD34 (clone QBEnd/10, mouse monoclonal), CD138 (clone B-A38, mouse monoclonal), kappa (rabbit polyclonal), lambda (rabbit polyclonal), and Myeloperoxidase (rabbit polyclonal) as previously described (<https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>). Reactions were revealed by the HRP-DAB Detection Kit (UCS Diagnostic, Rome, Italy).

Transmission electron microscopy (TEM)

One cubic millimeter of tissue from each collected specimen was fixed in 4% paraformaldehyde and post-fixed in 2% osmium tetroxide. After washing with 0.1 M phosphate buffer, the sample was dehydrated by a series of incubations in 30, 50, and 70% ethanol. Dehydration was continued by incubation steps in 95% ethanol, absolute ethanol, and propylene oxide; then, samples were embedded in EPON (Agar Scientific, Stansted Essex CM24 8GF United Kingdom). Eighty micrometers ultra-thin sections were mounted on copper grids and observed with MORGAGNI 268 D transmission electron microscope (FEI, Hillsboro, Oregon, USA).

Whole exome sequencing and data pre-processing

Genomic DNA was extracted from peripheral blood samples using standard procedures and the Qiagen blood DNA mini Kit (Qiagen, Hilden, Germany). Library pre-paration and whole exome capture were performed by using the Twist Human Core Exome Kit (Twist Bioscience, South San Francisco, CA, USA) according to the manufacturer's protocol and sequenced on the Illumina NovaSeq 6000 platform. The BaseSpace pipeline (Illumina, Inc., San Diego, CA, USA) and the TGex software (LifeMap Sciences, Inc., Alameda, CA, USA) were used for the variant calling and annotating variants, respectively. Sequencing data were aligned to the hg19 human reference genome. A minimum depth coverage of 30X was considered suitable for analysis, based on the guidelines of the American College of Medical Genetics and Genomics. All variants were examined for coverage and Qscore (minimum threshold of 30) and visualized by the Integrative Genome Viewer.

REFERENCES

1. Andreano E, Nicastrì E, Paciello I, Pileri P, Manganaro N, Piccini G, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. *Cell*. 2021;184:1821–35.e16.
2. Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. *Cell*. 2021;184:3452–66.e18.
3. Gossen J, Albani S, Hanke A, Joseph BP, Bergh C, Kuzikov M, et al. A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics. *ACS Pharm Transl Sci*. 2021;4:1079–95.
4. Platto S, Xue T, Carafoli E. COVID19: an announced pandemic. *Cell Death Dis*. 2020;11:799.
5. Santoro MG, Carafoli E. Remdesivir: from Ebola to COVID-19. *Biochem Biophys Res Commun*. 2021;538:145–50.
6. Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, et al. Inhibition of HECT E3 ligases as potential therapy for COVID-19. *Cell Death Dis*. 2021;12:310.
7. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. *Cell Cycle*. 2012;11:3638–48.
8. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ*. 2020;27:1451–4.
9. Celardo I, Pace L, Cifaldi L, Gaudio C, Barnaba V. The immune system view of the coronavirus SARS-CoV-2. *Biol Direct*. 2020;15:30.
10. Forni G, Mantovani A, Covid-19 Commission of Accademia Nazionale dei Lincei Rome. COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ*. 2021;28:626–39.
11. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384:2092–101.
12. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384:2124–30.
13. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384:2202–11.
14. Greinacher A. CLINICAL PRACTICE. Heparin-induced thrombocytopenia. *N Engl J Med*. 2015;373:252–61.
15. Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, Garcia de Frutos P, et al. Whole-exome sequencing in evaluation of patients with venous thromboembolism. *Blood Adv*. 2017;1:1224–37.
16. Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. *J Intern Med*. 2015;277:294–305.
17. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. *N Engl J Med*. 2021;384:1964–5.
18. Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *Lancet*. 2021;397:e11.
19. Hunter PR. Thrombosis after covid-19 vaccination. *BMJ*. 2021;373:n958.
20. See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination. *JAMA*. 2021;325:2448–56.
21. Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol*. 2020;13:120.
22. Sorvoll IH, Horvei KD, Ernstsen SL, Laegreid IJ, Lund S, Gronli RH, et al. An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. *J Thromb Haemost*. 2021;19:1813–8.
23. Perdomo J, Leung HHL, Ahmadi Z, Yan F, Chong JHH, Passam FH, et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. *Nat Commun*. 2019;10:1322.

ACKNOWLEDGEMENTS

The authors thank Richard Knight for helpful and constructive criticisms.

AUTHOR CONTRIBUTIONS

AM, IA, GN, GM, and YS supervised the research and wrote the manuscript. MS, RM, AN, FDL, SF, CC, RT, MC, QS, and YW conducted the research and YS analyzed the data. All the authors approved the final version of the manuscript.

FUNDING

This work was supported by the Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM (IG#20473; 2018–2022), to IA (AIRC Start-Up ID 23219; 2020–2024), Ministry of Health & MAECI Italy-China Science and Technology Cooperation (#PGR00961) to GM. It was also supported by Regione Lazio through LaziInnova Progetto Gruppo di Ricerca n 85-2017-14986; n 33 & 55-2021-T0002E0001 to GM, n A0375-2020-36663 GecoBio-mark to GN, and Rome Foundation (Italy, Prot 317 A/I) to GN.

COMPETING INTERESTS

YS is Editor-in-Chief, GM is Deputy Editor, IA and YW are editorial board members of Cell Death & Disease.

ETHICS STATEMENT

All the procedures carried out in the research with participation of humans were in compliance with the ethical standards of the institutional and/or national ethics committee and with the Helsinki Declaration of 1964 and its subsequent changes or with comparable ethics standards according to Italian Ministry of Health regulation, respecting ethics and safety.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-021-04058-z>.

Correspondence and requests for materials should be addressed to A.M., G.N. or G.M.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021